PREDICTION OF ACTIVE COMPOUNDS OF MUNTINGIA CALABURA AS POTENTIAL TREATMENT FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASES BY NETWORK PHARMACOLOGY INTEGRATED WITH MOLECULAR DOCKING

Keyphrases

• Active Compounds 100%
• ADRB2 20%
• Affinity Values 20%
• AKT1 20%
• Antiprotease 20%
• Betweenness Centrality 20%
• Binding Affinity 20%
• Bioinformatics 20%
• Centrality Values 20%
• Chronic Obstructive Pulmonary Disease 100%
• Chronic Obstructive Pulmonary Disease Treatment 20%
• Closeness Centrality 20%
• Closeness Degree 20%
• CXCR2 20%
• Degree Value 20%
• Disease Conditions 20%
• ELANE 20%
• Electronic Cigarettes 100%
• GADPH 20%
• Gene Targeting 20%
• Health Impact 20%
• HSPA1A 20%
• Interactions between Genes 20%
• Intercellular Adhesion molecule-1 (ICAM-1) 20%
• Matrix metalloproteinase-9 (MMP-9) 60%
• Methoxyflavones 20%
• Molecular Docking 100%
• Molecular Docking Analysis 20%
• Muntingia Calabura 100%
• Natural Sources 20%
• Network Pharmacology 100%
• Neutrophils 20%
• Pharmacological Effects 20%
• PI3K-Akt Pathway 20%
• Potential Treatments 100%
• Protease 20%
• Protein Pathway 20%
• Protein-protein Interaction 20%
• Safer Alternatives 20%
• Smoke Cessation 20%
• Vapers 20%
• Vascular Endothelial Growth Factor 20%

Biochemistry, Genetics and Molecular Biology

• AKT1 33%
• Binding Affinity 33%
• Conformation 33%
• Docking (Molecular) 100%
• Gelatinase B 100%
• HSPA1A 33%
• ICAM-1 33%
• Intimacy 33%
• MMP9 100%
• Protease 66%
• Protein-Protein Interaction 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Chronic Obstructive Lung Disease 100%
• Combination Therapy 16%
• Electronic Cigarette 83%
• Gelatinase B 50%
• Intercellular Adhesion Molecule 1 16%
• Network Pharmacology 100%
• Oroxylin A 16%
• Proteinase 16%
• Proteinase Inhibitor 16%